Less than two years later (of the IPO), and the 72-year-old (Timothy Springer) has ridden a 17,000% return in his Moderna shares — which he paid about $5 million for in the company’s early stages — into the billionaire club.
The Cambridge, Mass., biotech has jumped 162% this year, as of Wednesday’s close, surging on hopes for its mRNA-1273 coronavirus vaccine, one of the first (along with five other vaccines) to begin human trials.
The Cambridge, Mass., biotech has jumped 162% this year, as of Wednesday’s close, surging on hopes for its mRNA-1273 coronavirus vaccine, one of the first (along with five other vaccines) to begin human trials.
https://www.marketwatch.com/investing/stock/MRNA?countrycode...